Click on a filter below to refine your search. Remove a filter to broaden your search.
The findings were seen regardless of vaccination status and history of prior infection.
An increased incidence of myocardial infarction and pulmonary embolism were seen in the second week after first dose of Oxford-AstraZeneca vaccine.
However, from 13 to 52 weeks after COVID-19, no increase was seen for diabetes mellitus or cardiovascular disease.
The clinical lexicon presents data elements related to cardiovascular and noncardiovascular complications of COVID-19.
An increased risk for incident cardiovascular disease also was observed among those not hospitalized during acute phase.
And one in four COVID-19 survivors says the virus affected their heart health.
Lower hospitalization rates were seen at 14, 21 and 28 days for high-risk patients with mild-to-moderate COVID-19 who received casirivimab-imdevimab.